Patricia A. Steinert, Ph.D.
Affiliations: | 2012 | Health Sciences | University of Wisconsin-Milwaukee, Milwaukee, WI |
Area:
General, Public HealthGoogle:
"Patricia Steinert"Parents
Sign in to add mentor| Ron A. Cisler | grad student | 2012 | UW-Milwaukee | |
| (Predictors of healthcare cost in a Wisconsin acute leukemia population: Utilization of a state-level all payer claims database.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Auletta JJ, Kou J, Chen M, et al. (2023) Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy |
| Mau LW, Preussler JM, Meyer C, et al. (2022) Trends in Allogeneic Hematopoietic Cell Transplantation Utilization And Estimated Unmet Need among Medicare Beneficiaries with Acute Myeloid Leukemia. Transplantation and Cellular Therapy |
| Phelan R, Chen M, Bupp C, et al. (2022) Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy |
| Duncan C, St Martin A, Pérez WS, et al. (2021) Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. Pediatric Blood & Cancer. e29067 |
| D'Souza A, Fretham C, Lee SJ, et al. (2020) Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Mau LW, Preussler JM, Burns LJ, et al. (2020) Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach. Pharmacoeconomics |
| Ho VT, Martin AS, Pérez WS, et al. (2019) Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Mau LW, Meyer C, Burns LJ, et al. (2019) Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia. Jnci Cancer Spectrum. 3: pkz048 |
| Jaglowski S, Hu Z, Zhang Y, et al. (2019) Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry Blood. 134: 766-766 |
| Grupp S, Hu Z, Zhang Y, et al. (2019) Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry Blood. 134: 2619-2619 |